Nader Sanai

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Nader Sanai sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 6 currently recruiting 1 completed early-phase tilt top decile by trial count

Nader Sanai: 13 sponsored US clinical trials, 6 recruiting.

Nader Sanai sponsors 13 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glioblastoma, with 4 trials.

Top-decile sponsor footprint

Nader Sanai ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING Early Phase 1

BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

NCT07485049
RECRUITING Early Phase 1

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

NCT07268053
RECRUITING Early Phase 1

Clinical Trial of BMS-986504 in Recurrent GBM Patients

NCT06883747
RECRUITING Phase 2

Abemaciclib in Newly Diagnosed Meningioma Patients

NCT05940493
RECRUITING Early Phase 1

Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

NCT05773326
RECRUITING Early Phase 1

Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma

NCT04559685
ACTIVE NOT RECRUITING Early Phase 1

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

NCT06824662
ACTIVE NOT RECRUITING Early Phase 1

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients

NCT05182905
ACTIVE NOT RECRUITING Early Phase 1

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

NCT05076513
ACTIVE NOT RECRUITING Early Phase 1

Study of Pamiparib in Newly Diagnosed and rGBM

NCT04614909
ACTIVE NOT RECRUITING Early Phase 1

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

NCT02933736
TERMINATED Early Phase 1

Infigratinib in Recurrent High-Grade Glioma Patients

NCT04424966
COMPLETED Early Phase 1

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

NCT04391595

Phase Distribution

PhaseTrial count
Phase 1 12
Phase 2 1

Therapeutic Areas

Glioblastoma 4
Glioblastoma Multiforme 4
Glioma, Malignant 3
Glioma 3
Glioblastoma WHO Grade IV 2
Meningioma 2
High Grade Glioma 2
Brain Metastasases 1
Glioblastoma (GBM) 1
Glioblastoma Multiforme, Adult 1

What is open in the Nader Sanai pipeline

6 recruiting of 13 indexed (46% open); 1 completed (8%).

Phase mix: 0 late (III/IV) vs 13 early (I/II) (early-phase heavy).

Top condition: Glioblastoma (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Nader Sanai: open-pipeline peers nationwide

Peers matched on 13 registered trials and 46% open enrollment, not the therapeutic-area sidebar.

Nader Sanai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%10%20%30%40%50% Total trials Recruiting share Nader SanaiAdaptimmuneAgennixAkili Interactive LabsAlumisPraxis Precision MedicinesRetina Foundation of the SouthwestSouthern College of OptometryNRG Oncology
Nader Sanai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Nader Sanai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 46% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Nader Sanai page

13 registered trials is a research-attention snapshot, not an endorsement of Nader Sanai or any single study.

  • 6 of Nader Sanai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Glioblastoma is the condition Nader Sanai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glioblastoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nader Sanai pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.